Nantahala Capital Management LLC Has $7.22 Million Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Nantahala Capital Management LLC boosted its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 424.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,049,676 shares of the company's stock after buying an additional 849,676 shares during the quarter. Nantahala Capital Management LLC owned 3.51% of Silence Therapeutics worth $7,222,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. bought a new position in Silence Therapeutics in the 4th quarter worth about $26,000. Barclays PLC increased its position in shares of Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after purchasing an additional 2,793 shares during the period. GAMMA Investing LLC raised its stake in shares of Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock worth $42,000 after buying an additional 5,233 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Silence Therapeutics in the 4th quarter worth $69,000. Finally, Virtus ETF Advisers LLC raised its stake in shares of Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock worth $74,000 after buying an additional 6,098 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SLN. BMO Capital Markets decreased their target price on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Morgan Stanley lowered their target price on Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th. Finally, The Goldman Sachs Group lowered their target price on Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating on the stock in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

Silence Therapeutics Stock Up 8.4 %

Shares of NASDAQ:SLN traded up $0.31 on Thursday, reaching $4.01. The company had a trading volume of 237,984 shares, compared to its average volume of 296,123. Silence Therapeutics plc has a twelve month low of $1.97 and a twelve month high of $24.38. The stock has a 50-day moving average price of $3.50 and a 200 day moving average price of $7.27. The stock has a market capitalization of $120.02 million, a P/E ratio of -2.55 and a beta of 1.25.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.